在记忆评估服务中对痴呆症药物做出决定时的影响因素; 一个专注的民族学和采访研究
Rachael Kelley1, Claire A Surr1, Gregor Russell2
1Centre for Dementia Research, Leeds Beckett University, Leeds, UK.
Journal of geriatric psychiatry and neurology
|August 2, 2025
概括
关于痴呆症药物的决定通常基于感知到的风险,而不是由于沟通挑战而证明的好处. 对患者和临床医生来说,需要对药物风险和益处提供更清晰,标准化的信息.
科学领域:
- 老年学是一门学科.
- 药理学 药理学是指药理学的学科.
- 沟通研究 沟通研究
背景情况:
- 讨论痴呆症药物是复杂的,因为疾病的变化,有限的治疗方案,和沟通障碍.
- 在痴呆症护理中,共享决策往往受到限制.
- 这项研究调查了临床实践中围绕痴呆症药物治疗的沟通动态.
研究的目的:
- 检查痴呆症药物如何在临床环境中讨论.
- 了解影响有关痴呆症药物治疗决策的因素.
- 在痴呆症药物讨论中确定沟通策略和信息需求.
主要方法:
- 利用14个临床预约的专注视频/音频民族学.
- 对23名患者/支持者和5名临床医生进行了半结构化采访.
- 采用定性方法来分析沟通实践和决策过程.
主要成果:
- 确定了"在不确定性背景下对信息的框架和理解"和"不值得冒风险"或"没有什么可失去"的主题.
- 风险感知显著影响了决策,特别是对于脆弱的患者,当好处不确定时.
- 临床医生的信息框架,通常是基于经验,影响患者和支持者的选择.
结论:
- 临床医生必须认识到他们在患者决策中的影响力和他们的意见框架.
- 临床医生需要标准化的信息来源,以普遍传达药物的益处和副作用.
- 为患者和亲属提供可访问的信息对于明智的决策至关重要,因为人们对痴呆症药物治疗的不确定性很大.
相关概念视频
Dementia
165
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
165
Alzheimer's Disease: Treatment
262
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
262
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
206
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
206
Alzheimer's Disease: Overview
669
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
669
Factors Affecting Drug Response: Overview
2.4K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
2.4K
Ethical Dilemmas II
1.3K
Resolving an ethical dilemma in healthcare involves a systematic approach that considers every aspect of the issue, respecting both the patient's needs and values and the healthcare professional's ethical obligations. Here are potential steps to resolve an ethical dilemma:
1.3K


